COVID-19 Industry News

5 May 2020: Curium Technescan HDP - Substitute Product Available
Landauer Radiopharmacuticals wishes to notify the Nuclear Medicine Community that Technesacn HDP (091D0AU) for skeletal imaging, is currently in short supply. This product is manufactured by Curium in their USA factory. 
Please click on the the link below for the full statement:
15 April 2020: SNMMI 2020 Annual Meeting Update
SNMMI is receiving many inquiries about the status of the upcoming Annual Meeting, planned for June 13-16 in New Orleans. We are aware that most of you are operating under severe restrictions meant to protect your health and that of your patients, staff and families. SNMMI leadership is watching very closely as the situation progresses—in New Orleans, in the United States and worldwide.
The New Orleans Convention Center is currently closed and has been converted to a massive field hospital. Of course, we have thought about all options for our scientific sessions, including an alternative virtual meeting option, and it is the SNMMI Board of Directors’ duty and fiduciary responsibility to lessen the Society’s losses while protecting the health and safety of our attendees. We are in active consultation with SNMMI legal counsel as well as officials in the state of Louisiana, and we will announce our decision in a timely manner.
In the meantime, we have created a detailed contingency plan for an interactive virtual meeting that is both informative and appealing, including continuing education, scientific abstracts, posters, exhibits and networking. We are continuing to fine-tune this plan so that it can be promptly implemented.
Hope you and your family are safe, and I am grateful for your commitment and support of the Society.
Vasken Dilsizian, MD
SNMMI president
8 April 2020: COVID-19 Guidelines: An Information Statement from ASNC and SNMMI
Please see attachment below on "Guidance and Best Practices for Nuclear Cardiology Laboratories during the Coronavirus Disease 2019 (COVID-19) Pandemic: An Information Statement from ASNC and SNMMI".
1 April 2020: IAEA to Ship Vital Testing Equipment to Countries in the Fight against COVID-19
The International Atomic Energy Agency (IAEA) is dispatching a first batch of equipment to more than 40 countries to enable them to use a nuclear-derived technique to rapidly detect the coronavirus that causes COVID-19. This emergency assistance is part of the IAEA’s response to requests for support from around 90 Member States in controlling an increasing number of infections worldwide. Showing strong support for the initiative, several countries have announced major funding contributions for the IAEA’s efforts in helping to tackle the pandemic.  
Read the full article here.
Related resources:
1 April 2020: European Society of Radiology, Webinar Live & Free: Italian experts share COVID-19 experience.  April 1 on ESR Connect

The IAEA continues to join forces with partner professional organizations to support our colleagues in dealing with this unprecedented health crisis.

We invite you to join, on April 1st, 2020 | 17:00 CET, the webinar organized by the European Society of Radiology in which Italian experts will share their experiences.

Join us for a second episode of radiology fighting COVID-19, featuring two renowned colleagues from northern Italy sharing their experience in fighting the disease.

After the first immensely successful episode, Prof. Nicola Sverzellati from Parma, Italy, made himself available again to answer more of the numerous questions raised by the audience. Joining him is Francesco Sardanelli, Professor of Radiology at the University of Milan and Head of Radiology at the Research Hospital (IRCCS) Policlinico San Donato.

Get valuable insights on imaging workflows, as well as staff protection, prevention measures and department management based on experiences from two regions being among the most affected areas in Europe to date. 

Hosted by ESR Second Vice-President Dr. Adrian Brady from Cork, Ireland.


In spite of challenging times, the ESR remains committed to public health and the fight against the novel coronavirus disease.

 European Society of Radiology (ESR)
Am Gestade 1, 1010 Vienna, Austria
+43 1 533 40 64-0
© 2019 European Society of Radiology (ESR)

29 March 2020: IAEA COVID-19 Webinar: Challenges for Nuclear Medicine Departments - Recorded Version
The IAEA, in collaboration with International Organizations, is committed to supporting nuclear medicine facilities cope with the current COVID-19 pandemic.  On Wednesday March 25th, the IAEA held a webinar on the Challenges for Nuclear Medicine Departments. The webinar was a virtual town-hall meeting, in which an international panel of experts answered a series of questions related to how to deal with COVID-19 in nuclear medicine departments.
The webinar addressed practical considerations and challenges including:
  1. Site readiness
  2. Prevention and hygiene
  3. Patient scheduling
  4. Patient management
  5. Radionuclide therapies
  6. Support to radiology departments
  7. What to do if a team member is COVID-19 positive?
This webinar also functioned as a platform to share and exchange experiences and ask questions.

Andrew Scott (Australia), Henry Bom (S. Korea), Jimmy Bomanji (UK), Juliano Cerci (Brazil), Arturo Chiti (Italy), Johannes Czernin (US), Stefano Fanti (Italy), Marcus Hacker (Austria), Ken Hermann (Germany), Mike Sathekge (S. Africa).

Diana Paez (IAEA)
Gopinath Gnanasegaran

Please refer to the following link to access the full recorded webinar:
26 March 2020: Update - Aerosol Generating Procedures: Addendum (Cyclomedica)
The ANZSNM made an enquiry in relation to Cyclomedica's recent statement on Aerosol Generating Procedures (23 March 2020) . Specifically, it was whether the "terminal trap is biologically active in stopping the COVID-19 virus if exhaled during a procedure".
The full response to this from Cyclomedica is attached below as an addendum. 
23 March 2020: Statement from Cyclomedica Australia: Technegas and COVID-19
Please see attached below, statements from Cyclomedica Australia regarding the Technegas in the current COVID-19 environment.
For further information, please contact
17 March 2020: Technegas use and COVID-19

In response to the QEH seeking confirmation, we have received the following information from the Cyclomedica team:

As you would be aware there have been a number of queries from customers in different parts of the globe, prompted by concerns about the COVID-19 corona virus. 

 With regards to your query please see the points below to help provide some clarity:   

    • In over 30 years of use, in approximately 4 million clinical diagnostic procedures around the world, there have been no reported viral or other disease cross-contamination events associated with the Technegas™ System.
    • Technegas™ as a diagnostic agent has been omnipresent in nuclear medicine/respiratory settings throughout other global viral outbreaks such as SARS in the early 2000s, without any known or reported issues.   
    • The patient administration set (PAS), used to deliver the Technegas™ to a patient’s lungs,  is a single use CE marked medical device which must be discarded after one Technegas™ procedure.
    • The PAS has a one-way valve and special filter to trap exhaled air from the patient’s lungs. 
    • Hospitals / clinics should continue to follow their own local infection control procedures when conducting ventilation-perfusion (and other) procedures involving patients with suspected viral or contagious conditions. 

The PAS filter contains a bidirectional hydrophobic membrane designed to prevent cross contamination and that we can attest to the fact that in the years that this filter has been used in association with the Techengas™ Generators, there have been no reported instances of cross-contamination."


13 March 2020: SNMMI President’s Statement on COVID-19 and the SNMMI 2020 Annual Meeting 

Dear SNMMI Members,

Much like you, the SNMMI leadership has been closely following the rapidly evolving COVID-19 situation—monitoring the latest recommendations provided by the U.S. Centers for Disease Control and Prevention (CDC) and the World Health Organization (WHO) to help address its inevitable impact on the nuclear medicine and molecular imaging community.

We are aware that many of your organizations now have temporary travel policies in place to best protect the health of your patients, as well as yours and that of your staff. Given the importance of your work, we are pleased to hear of this quick response being implemented to help limit any outbreak at your institutions, as well as limiting exposure to any patient populations.

We also understand that because of the critical work you do, providing you with unparalleled learning opportunities to examine the latest research and clinical applications helping transform medicine and improve lives remains essential.

So, despite these uncertainties we are currently planning to hold the SNMMI 2020 Annual Meeting as scheduled, June 13-16 in New Orleans. We are also exploring multiple alternate scenarios that will allow us to move forward with producing a positive, enriching Annual Meeting experience. We recognize the situation remains fluid for families and organizations as healthcare officials and governments continue to work to contain this outbreak and we will continue to adjust, as needed.

Public safety is of the utmost importance and SNMMI will make any and all decisions related to this health crisis with that as our guiding principal. To keep you informed, the COVID-19 page on our 2020 Annual Meeting website will be updated frequently as new information becomes available.

We thank you for your patience and understanding while we explore the best possible solutions to serve you and the nuclear medicine and molecular imaging community during this challenging time.

Warm Regards,

Vasken Dilsizian, MD
SNMMI President